Werewolf Therapeutics (HOWL) News Today $1.22 -0.07 (-5.43%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.25 +0.03 (+2.87%) As of 06/13/2025 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOWL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Werewolf Therapeutics to Participate in the BIO International ConventionJune 12 at 8:00 AM | globenewswire.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Sold by Millennium Management LLCMillennium Management LLC trimmed its stake in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) by 55.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 596,289 shares of the company'sJune 6, 2025 | marketbeat.comWerewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comWerewolf Therapeutics’ SWOT analysis: innovative platform drives stock potentialMay 24, 2025 | investing.comWerewolf Therapeutics Stock Price, Quotes and ForecastsMay 20, 2025 | benzinga.comHonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124May 20, 2025 | globenewswire.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Acquires $159,288.22 in StockMay 15, 2025 | insidertrades.comWerewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development SummitMay 13, 2025 | globenewswire.comWerewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | finanznachrichten.deWerewolf Therapeutics Announces Q1 2025 Financial ResultsMay 9, 2025 | msn.comWerewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comWerewolf Therapeutics reports progress on IBD treatmentMay 6, 2025 | investing.comWerewolf Therapeutics to Participate in Upcoming Investor ConferencesMay 5, 2025 | globenewswire.comWerewolf Therapeutics appoints Bloom as Chief Business OfficerApril 17, 2025 | markets.businessinsider.comWerewolf Therapeutics Appoints Steven Bloom as Chief Business OfficerApril 17, 2025 | globenewswire.comWatch: First dire wolf’s howl for 10,000 years after scientists bring extinct species ‘back to life’April 8, 2025 | msn.comWerewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comWerewolf Therapeutics (HOWL) Gets a Buy from Bank of America SecuritiesMarch 28, 2025 | markets.businessinsider.comWedbush Research Analysts Cut Earnings Estimates for HOWLWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Analysts at Wedbush reduced their FY2025 earnings per share estimates for shares of Werewolf Therapeutics in a report released on Wednesday, March 12th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($1.84) per shaMarch 17, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Outlook for HOWL EarningsWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2025 earnings estimates for Werewolf Therapeutics in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now expects that the companyMarch 17, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Werewolf Therapeutics (HOWL), Exelixis (EXEL)March 13, 2025 | markets.businessinsider.comWerewolf Therapeutics' (HOWL) Outperform Rating Reiterated at WedbushWedbush restated an "outperform" rating and set a $8.00 target price on shares of Werewolf Therapeutics in a report on Wednesday.March 13, 2025 | marketbeat.comWerewolf Therapeutics' (HOWL) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research report on Wednesday.March 13, 2025 | marketbeat.comWerewolf Therapeutics (NASDAQ:HOWL) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPSWerewolf Therapeutics (NASDAQ:HOWL - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.March 12, 2025 | marketbeat.comWerewolf Therapeutics (NASDAQ:HOWL) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPSWerewolf Therapeutics (NASDAQ:HOWL - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.March 12, 2025 | marketbeat.comWerewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with ChinaMarch 12, 2025 | tipranks.comWerewolf Therapeutics Reports 2024 Financial Results and ProgressMarch 12, 2025 | tipranks.comWerewolf Therapeutics reports Q4 EPS (46c), consensus (31c)March 11, 2025 | markets.businessinsider.comWerewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 11, 2025 | globenewswire.comWerewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma ConferenceMarch 4, 2025 | globenewswire.comWerewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on ThursdayWerewolf Therapeutics (NASDAQ:HOWL) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comWerewolf Therapeutics appoints Anil Singhal to board of directorsFebruary 24, 2025 | markets.businessinsider.comWerewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of DirectorsFebruary 24, 2025 | globenewswire.comShort Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Rises By 13.2%Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,720,000 shares, a growth of 13.2% from the December 31st total of 1,520,000 shares. Approximately 5.2% of the company's stock are short sold. Based on an average daily trading volume, of 773,000 shares, the days-to-cover ratio is presently 2.2 days.February 3, 2025 | marketbeat.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in DecemberWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,720,000 shares, a growth of 13.2% from the December 15th total of 1,520,000 shares. Based on an average daily trading volume, of 773,000 shares, the days-to-cover ratio is currently 2.2 days. Currently, 5.2% of the company's shares are short sold.January 18, 2025 | marketbeat.comWerewolf Therapeutics price target lowered to $4 from $12 at JMP SecuritiesJanuary 14, 2025 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Werewolf Therapeutics (HOWL)January 14, 2025 | markets.businessinsider.comWerewolf Therapeutics (NASDAQ:HOWL) Price Target Lowered to $4.00 at JMP SecuritiesJMP Securities cut their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a "market outperform" rating for the company in a research report on Tuesday.January 14, 2025 | marketbeat.comWerewolf Therapeutics provides business update, highlights 2025 outlookJanuary 14, 2025 | markets.businessinsider.comBuy Rating Affirmed for Werewolf Therapeutics Amid Strategic Advancements and Strong Financial PositionJanuary 14, 2025 | markets.businessinsider.comWerewolf Therapeutics, Inc.: Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic OutlookJanuary 13, 2025 | finanznachrichten.deWerewolf Therapeutics Provides Business Update and Highlights 2025 Strategic OutlookJanuary 13, 2025 | globenewswire.comBank of America Securities Sticks to Their Buy Rating for Werewolf Therapeutics (HOWL)January 7, 2025 | markets.businessinsider.comShort Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Expands By 23.6%Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 1,520,000 shares, an increase of 23.6% from the November 30th total of 1,230,000 shares. Based on an average daily trading volume, of 744,600 shares, the short-interest ratio is currently 2.0 days. Approximately 4.6% of the company's stock are sold short.December 31, 2024 | marketbeat.comShort Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 6.1%Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 1,230,000 shares, a decline of 6.1% from the November 15th total of 1,310,000 shares. Based on an average trading volume of 712,600 shares, the short-interest ratio is currently 1.7 days. Approximately 3.8% of the shares of the stock are short sold.December 17, 2024 | marketbeat.comWerewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare ConferenceNovember 20, 2024 | globenewswire.comInnovative Cytokine Immunotherapy: Werewolf Therapeutics’ Pioneering Approach and Promising PipelineNovember 19, 2024 | markets.businessinsider.comWerewolf Therapeutics' (HOWL) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday.November 19, 2024 | marketbeat.comFY2024 Earnings Estimate for HOWL Issued By Leerink PartnrsWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Werewolf Therapeutics in a report issued on Monday, November 11th. Leerink Partnrs analyst D. Graybosch now forecasts that the comNovember 13, 2024 | marketbeat.comPromising Potential of Werewolf Therapeutics’ INDUKINE Platform Despite ChallengesNovember 13, 2024 | markets.businessinsider.com Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address HOWL Media Mentions By Week HOWL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HOWL News Sentiment▼0.930.88▲Average Medical News Sentiment HOWL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HOWL Articles This Week▼21▲HOWL Articles Average Week Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aardvark Therapeutics News Lifecore Biomedical News Zhengye Biotechnology News Esperion Therapeutics News DBV Technologies News MediWound News Y-mAbs Therapeutics News Instil Bio News Acelyrin News I-Mab News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HOWL) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HOWL Stock Free HOWL Stock Alerts